Subcutaneous ketamine in the treatment of depression and suicide risk: case report.
Introduction Several studies have shown that ketamine, an NMDA receptor antagonist, represents a promising alternative in treating depression and suicide. The intranasal or intravenous use of ketamine, currently used, has limitations in terms of cost and complexity. The subcutaneous (SC) route may...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2023-03-01
|
| Series: | European Psychiatry |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933823021454/type/journal_article |
| _version_ | 1797617334125330432 |
|---|---|
| author | M. A. Cigognini D. V. D. Meene |
| author_facet | M. A. Cigognini D. V. D. Meene |
| author_sort | M. A. Cigognini |
| collection | DOAJ |
| description |
Introduction
Several studies have shown that ketamine, an NMDA receptor antagonist, represents a promising alternative in treating depression and suicide. The intranasal or intravenous use of ketamine, currently used, has limitations in terms of cost and complexity. The subcutaneous (SC) route may be an affordable alternative for the treatment of depression and suicidality.
Objectives
To evaluate the response of SC ketamine (0,5 mg/kg) applications on depressive, anxiety, and suicide symptoms.
Methods
A patient with unipolar depression and suicide attempt was submitted to 3 sessions of SC ketamine (0,5 mg/kg). The applications had 2 days of intervals. Clinical evaluations were measured by BDI, BSI, and BAI. The vital signs were monitored under 2 hours after injections and the potential side effects.
Results
Changes in measurement instruments according to applications can be seen in Tab 1:
BDI
BSI
BAI
Application 1
26
14
18
Application 2
03
00
00
Application 3
02
00
00
The average measurements of vital signs during 2 hours of monitoring for each application can be seen in Tab 2:
BP
HR
RF
OX
ECG
Nine measurements (average)
123/80
78,86
17,55
99%
NP
Conclusions
The use of SC ketamine showed remission in BDI, BSI and BAI, respectively demonstrated safety in use.
Disclosure of Interest
None Declared |
| first_indexed | 2024-03-11T07:54:20Z |
| format | Article |
| id | doaj.art-3f3d22f47c86496fb18d5009390ca558 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:54:20Z |
| publishDate | 2023-03-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-3f3d22f47c86496fb18d5009390ca5582023-11-17T05:06:00ZengCambridge University PressEuropean Psychiatry0924-93381778-35852023-03-0166S1010S101110.1192/j.eurpsy.2023.2145Subcutaneous ketamine in the treatment of depression and suicide risk: case report.M. A. Cigognini0D. V. D. Meene1Psychiatry, Institute and Department of Psychiatry of Clinics Hospital of the University of São Paulo Medical School, São PauloPsychiatry, Instituto de Neurosciência & Comportamento, Blumenau, Brazil Introduction Several studies have shown that ketamine, an NMDA receptor antagonist, represents a promising alternative in treating depression and suicide. The intranasal or intravenous use of ketamine, currently used, has limitations in terms of cost and complexity. The subcutaneous (SC) route may be an affordable alternative for the treatment of depression and suicidality. Objectives To evaluate the response of SC ketamine (0,5 mg/kg) applications on depressive, anxiety, and suicide symptoms. Methods A patient with unipolar depression and suicide attempt was submitted to 3 sessions of SC ketamine (0,5 mg/kg). The applications had 2 days of intervals. Clinical evaluations were measured by BDI, BSI, and BAI. The vital signs were monitored under 2 hours after injections and the potential side effects. Results Changes in measurement instruments according to applications can be seen in Tab 1: BDI BSI BAI Application 1 26 14 18 Application 2 03 00 00 Application 3 02 00 00 The average measurements of vital signs during 2 hours of monitoring for each application can be seen in Tab 2: BP HR RF OX ECG Nine measurements (average) 123/80 78,86 17,55 99% NP Conclusions The use of SC ketamine showed remission in BDI, BSI and BAI, respectively demonstrated safety in use. Disclosure of Interest None Declaredhttps://www.cambridge.org/core/product/identifier/S0924933823021454/type/journal_article |
| spellingShingle | M. A. Cigognini D. V. D. Meene Subcutaneous ketamine in the treatment of depression and suicide risk: case report. European Psychiatry |
| title | Subcutaneous ketamine in the treatment of depression and suicide risk: case report. |
| title_full | Subcutaneous ketamine in the treatment of depression and suicide risk: case report. |
| title_fullStr | Subcutaneous ketamine in the treatment of depression and suicide risk: case report. |
| title_full_unstemmed | Subcutaneous ketamine in the treatment of depression and suicide risk: case report. |
| title_short | Subcutaneous ketamine in the treatment of depression and suicide risk: case report. |
| title_sort | subcutaneous ketamine in the treatment of depression and suicide risk case report |
| url | https://www.cambridge.org/core/product/identifier/S0924933823021454/type/journal_article |
| work_keys_str_mv | AT macigognini subcutaneousketamineinthetreatmentofdepressionandsuicideriskcasereport AT dvdmeene subcutaneousketamineinthetreatmentofdepressionandsuicideriskcasereport |